证券代码：300009 证券简称：安科生物 公告编号：2025-035 安徽安科生物工程（集团）股份有限公司 关于第八届董事会第二十次会议决议的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）第八届董事 会第二十次会议于 2025 年 7 月 10 日 9:30 以现场及通讯会议的方式召开。会议 通知于 2025 年 7 月 1 日以直接、邮件的形式送达。应到董事 12 人，实到董事 12 人，公司全体监事、高级管理人员列席会议。会议由公司董事长宋礼华先生 主持，会议召集及召开程序符合国家有关法律法规和公司章程的规定，与会董事 认真审议并形成了以下决议： 1、审议通过《关于公司<第4期员工持股计划（草案）>及其摘要的议案》 根据《公司法》《证券法》《关于上市公司实施员工持股计划试点的指导意见》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等 法律法规、规章及规范性文件的规定，同意公司拟实施第 4 期员工持股计划（以下 简称"本持股计划"），并提交公司股东大会审议。 本持股计 ...

Group 1 - The A-share pharmaceutical sector showed strong performance in the morning session, with notable gains in CRO, biopharmaceuticals, and innovative drugs [1] - Kangchen Pharmaceutical reached the daily limit increase, while Anke Bio surged over 6% [1] - Other stocks such as Kangtai Biological, Zhifei Biological, and Ganli Pharmaceutical also experienced upward movement [1]

Group 1: Company Performance - Northern Rare Earth expects a net profit of 900 million to 960 million yuan for the first half of 2025, representing a year-on-year increase of 1882.54% to 2014.71% [1] - Muyuan Foods anticipates a net profit of 10.5 billion to 11 billion yuan for the first half of 2025, reflecting a year-on-year growth of 924.6% to 973.39% [2] - Hongta Securities projects a net profit of 651 million to 696 million yuan for the first half of 2025, indicating a year-on-year increase of 45% to 55% [3] Group 2: Business Developments - Dazhihui clarifies that it has not engaged in businesses related to "stablecoins," "virtual asset trading," or "cross-border payments," following a significant stock price fluctuation [4] - Bluetech announces a share transfer agreement where its actual controller will change, with the Ma'anshan Municipal Government becoming the actual controller after the transfer of 18% of shares [5] Group 3: Industry Trends - Jiangsu Electric Power reports a 5.01% year-on-year increase in electricity generation for the first half of 2025 [6] - Jin'an Guoji anticipates a non-recurring net profit growth of 4700% to 6300% for the first half of 2025 [6] - New Beiyang expects a non-recurring net profit growth of 650% to 720% for the first half of 2025 [6]

Group 1: Stock Suspension and Resumption - BlueDai Technology's Zhu Tangfu plans to transfer 18% of the company's shares to Jiangdong Chantuo, leading to the resumption of trading [1] - *ST Yazhen's actual controller's tender offer period has expired, resulting in stock suspension [1] Group 2: Investment Cooperation and Operational Status - Anke Biotechnology has become the exclusive agent for the sales and marketing promotion of follicle-stimulating hormone products in mainland China and Hong Kong, Macau, and Taiwan [2] - Gaoxin Information Technology plans to raise no more than 374 million yuan through a private placement for the expansion of vehicle networking communication products, the Shenzhen R&D and operation center project, and to supplement working capital [2] - Zhongyan Chemical's affiliated company has signed an agreement worth 6.809 billion yuan to acquire mining rights for natural soda ash in the Naimanqi Daqintala area [3] - Jerry Holdings has received a project award letter from Algeria's national oil company for the Hodenus natural gas booster station EPC project, with a total award amount of approximately 850 million USD or 6.126 billion yuan [3] Group 3: Performance Changes - Northern Rare Earth expects a net profit of 900 million to 960 million yuan in the first half of 2025, representing a year-on-year increase of 1882.54% to 2014.71% [4] - Dongfang Precision Engineering anticipates a net profit of 361 million to 426 million yuan in the first half of 2025, with a year-on-year growth of 120% to 160% [4] - Gansu Energy expects a net profit of 800 million to 830 million yuan in the first half of 2025, reflecting a year-on-year increase of 178.95% to 189.41% [5] - Morning Light Biotechnology forecasts a net profit of 202 million to 232 million yuan in the first half of 2025, with a year-on-year growth of 102.33% to 132.38% [6] - Muyuan Foods expects a net profit of 10.5 billion to 11 billion yuan in the first half of 2025, representing a year-on-year increase of 924.60% to 973.39% [6] - Ganli Pharmaceutical anticipates a net profit of 460 million to 500 million yuan in the first half of 2025, with a year-on-year increase of 262.47% to 293.99% [6] - Hongta Securities expects a net profit of 651 million to 696 million yuan in the first half of 2025, reflecting a year-on-year growth of 45% to 55% [7] - Shandong Glass Fiber anticipates a net profit of 8.66 million to 12.99 million yuan in the first half of 2025, recovering from a loss of 97.31 million yuan in the same period last year [7]

智通财经7月9日电，安科生物(300009.SZ)公告称，公司及其全资子公司安科医药与晟济药业签署《产 品独家代理协议》，公司及安科医药将独家代理SJ02产品在中国大陆及港澳台地区的销售及营销推广。 SJ02是一种长效重组人卵泡刺激素(FSH-CTP)，有望成为国内首款获批上市的长效FSH-CTP。此次合作 旨在充分发挥双方优势资源，实现强强联合的协同效应，加速SJ02在中国市场的商业化落地进程。但同 时也存在产品上市时间存在不确定性、市场推广不及预期等风险。 安科生物：独家代理重组人卵泡刺激素-CTP融合蛋白注射液 ...

Core Viewpoint - Anke Biotech (300009) has signed an exclusive agency agreement with Shengji Pharmaceutical for the sales and marketing of SJ02, a recombinant human follicle-stimulating hormone-CTP fusion protein injection, in mainland China and Hong Kong, Macau, and Taiwan [1] Group 1 - SJ02, in combination with gonadotropin-releasing hormone antagonists, is intended for controlled ovarian stimulation and has the potential to be the first long-acting FSH-CTP approved in China [1] - The drug registration application was submitted to the National Medical Products Administration in December 2023, indicating a significant step towards market entry [1] - The collaboration aims to accelerate the commercialization of SJ02 in the Chinese market, enhancing the company's product portfolio in the assisted reproduction field and increasing its industry influence and profit growth [1]

证券代码：300009 证券简称：安科生物 公告编号：2025-034 安徽安科生物工程（集团）股份有限公司 关于独家代理重组人卵泡刺激素-CTP 融合蛋白注射液的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 鉴于上海宝济药业股份有限公司（以下简称"宝济药业"）全资子公司苏州晟 济药业有限公司（以下简称"晟济药业"）自主开发的重组人卵泡刺激素-CTP 融合 蛋白注射液（以下简称"SJ02"或"协议产品"）即将上市，安徽安科生物工程（集 团）股份有限公司（以下简称"公司"）及其全资子公司安徽安科医药有限公司（以 下简称"安科医药"）与晟济药业于 2025 年 7 月 9 日达成合作，并签署了《产品 独家代理协议》，公司及安科医药将独家代理 SJ02 产品在中国大陆及港澳台地区的 销售及营销推广。 晟济药业与公司不构成关联关系，根据《深圳证券交易所创业板股票上市规则》 《公司章程》等规定，本次事项无需提交董事会及股东大会审议。 一、合作方基本情况 名称：苏州晟济药业有限公司 股东：宝济药业持有晟济药业 66.1791%股权，苏州康聚生物科技有限公司持有 晟济药 ...

Core Viewpoint - The long-standing monopoly of Changchun High-tech in the long-acting growth hormone market has been broken by the approval of Teva's growth hormone injection, prompting both Changchun High-tech and Anke Bio to seek transformation and breakthroughs in response to increased market competition [1] Group 1: Company Developments - Anke Bio announced that its AK2024 injection has received approval for clinical trials in HER2-positive advanced solid tumors, leading to a nearly 8% increase in its stock price following the announcement [1] - The company has initiated an overseas product launch plan and is prioritizing research on breast cancer and gastric cancer for AK2024, a new anti-HER2 monoclonal antibody [1][2] - AK2024's mechanism involves blocking HER2 protein interactions and inhibiting key tumor signaling pathways, which significantly enhances its anti-tumor activity compared to existing treatments [2] Group 2: Financial Performance - Anke Bio reported a revenue of approximately 2.536 billion yuan in 2024, a year-on-year decrease of 11.51%, with a net profit of about 707 million yuan, down 16.56% [3] - In Q1 2025, the company continued to experience a decline in performance, with revenues of approximately 629 million yuan, a decrease of 4.17%, and a net profit of about 209 million yuan, down 4.02% [3] - The decline in revenue was attributed to decreased sales in key business segments, while increased marketing expenditures for new products further compressed profit margins [3] Group 3: Future Outlook - Anke Bio emphasizes that oncology will be a key focus area, with its first antibody drug, trastuzumab (brand name: Ansaiting), approved in October 2023, and multiple oncology products in clinical trials [4] - The company anticipates significant growth in sales of its trastuzumab product in 2025, alongside ongoing development in autoimmune disease treatments and other therapeutic areas [4]

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：300009 证券简称：安科生物 公告编号：2025-033 安徽安科生物工程（集团）股份有限公司 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、持有人会议召开情况 为保证公司第 3 期员工持股计划的顺利进行，保障持有人的合法权益，根据《第 3 期持股计划（草案）》等相关规定，同意设立公司第 3 期员工持股计划管理委员 会，监督本持股计划的日常管理，代表持有人行使股东权利。本持股计划管理委员 会由 3 名委员组成，设管理委员会主任 1 名，任期为本持股计划的存续期。 第 3 期员工持股计划第一次持有人会议决议的公告 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）第 3 期员工持 股计划（以下简称"本持股计划"）第一次持有人会议于 2025 年 7 月 1 日以通讯 表决方式召开，本次会议由公司董事、董事会秘书李坤先生召集和主持，出席本次 会议的持有人共 9 人，代表本持股计划份额 11,313,750 份，占本持股计划实际认购 总份额的 100%。 本次会议的召集、召开、表决程序符合有关法律、行政法规、部门规章、规范 性文件和《安徽安科生 ...